Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological diseasemodifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Heijde, D. van der; Wei, J.C.C.; Dougados, M.; Mease, P.; Deodhar, A.; Maksymowych, W.P.; ... ; COAST-V Study Grp (2018)

Article / Letter to editor

• All authors: Heijde, D. van der; Wei, J.C.C.; Dougados, M.; Mease, P.; Deodhar, A.; Maksymowych, W.P.; Bosch, F. van den; Sieper, J.; Tomita, T.; Landewe, R.; Zhao, F.Y.; Krishnan, E.; Adams, D.H.; Pangallo, B.; Carlier, H.; COAST-V Study Grp
• Date: 2018-12-08
• Journal: Lancet
• Volume: 392
• Issue: 10163
• Pages: 2441 - 2451
• DOI: doi:10.1016/S0140-6736(18)31946-9